Literature DB >> 10422797

Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene.

M S Meyn1.   

Abstract

Ataxia-telangiectasia (A-T) is a pleiotropic inherited disease characterized by neurodegeneration, cancer, immunodeficiencies, radiation sensitivity, and genetic instability. Although A-T homozygotes are rare, the A-T gene may play a role in sporadic breast cancer and leukemia. ATM, the gene responsible for A-T, is homologous to several cell cycle checkpoint genes from other organisms. ATM is thought to play a crucial role in a signal transduction network that modulates cell cycle checkpoints, genetic recombination, apoptosis, and other cellular responses to DNA damage. New insights into the pathobiology of A-T have been provided by the creation of Atm-/- mice and by in vitro studies of ATM function. Analyses of ATM mutations in A-T patients and in sporadic tumors suggest the existence of two classes of ATM mutation: null mutations that lead to A-T and dominant negative missense mutations that may predispose to cancer in the heterozygous state.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10422797     DOI: 10.1034/j.1399-0004.1999.550501.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  34 in total

Review 1.  Reverse genetic studies of homologous DNA recombination using the chicken B-lymphocyte line, DT40.

Authors:  E Sonoda; C Morrison; Y M Yamashita; M Takata; S Takeda
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-01-29       Impact factor: 6.237

Review 2.  Manipulating the mammalian genome by homologous recombination.

Authors:  K M Vasquez; K Marburger; Z Intody; J H Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

Review 3.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

4.  Abnormal white matter signal in ataxia telangiectasia.

Authors:  J J Ciemins; A L Horowitz
Journal:  AJNR Am J Neuroradiol       Date:  2000-09       Impact factor: 3.825

5.  The yeast TEL1 gene partially substitutes for human ATM in suppressing hyperrecombination, radiation-induced apoptosis and telomere shortening in A-T cells.

Authors:  E Fritz; A A Friedl; R M Zwacka; F Eckardt-Schupp; M S Meyn
Journal:  Mol Biol Cell       Date:  2000-08       Impact factor: 4.138

6.  UV-induced hyperphosphorylation of replication protein a depends on DNA replication and expression of ATM protein.

Authors:  G G Oakley; L I Loberg; J Yao; M A Risinger; R L Yunker; M Zernik-Kobak; K K Khanna; M F Lavin; M P Carty; K Dixon
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

7.  The radioprotective agent WR1065 protects cells from radiation damage by regulating the activity of the Tip60 acetyltransferase.

Authors:  Ye Xu; Kalindi Parmar; Fengxia Du; Brendan D Price; Yingli Sun
Journal:  Int J Biochem Mol Biol       Date:  2011-10-20

8.  Oxidative stress as a therapeutic perspective for ATM-deficient chronic lymphocytic leukemia patients.

Authors:  Veronika Navrkalova; Leona Raskova Kafkova; Vladimir Divoky; Sarka Pospisilova
Journal:  Haematologica       Date:  2015-08       Impact factor: 9.941

9.  DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity.

Authors:  Yingli Sun; Ye Xu; Kanaklata Roy; Brendan D Price
Journal:  Mol Cell Biol       Date:  2007-10-08       Impact factor: 4.272

10.  ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Authors:  Veronika Navrkalova; Ludmila Sebejova; Jana Zemanova; Jana Kminkova; Blanka Kubesova; Jitka Malcikova; Marek Mraz; Jana Smardova; Sarka Pavlova; Michael Doubek; Yvona Brychtova; David Potesil; Veronika Nemethova; Jiri Mayer; Sarka Pospisilova; Martin Trbusek
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.